

## References

### I-9904

1. AlphaNine SD prescribing information. Grifols. September 2021.
2. Alprolix prescribing information. Bioverativ. October 2020.
3. BeneFIX prescribing information. Pfizer. June 2020.
4. Idelvion prescribing information. CSL Behring. July 2021.
5. Ixinity prescribing information. Medexus Pharm, Inc. September 2021.
6. Mononine prescribing information. CSL Behring. December 2019.
7. Profilnine prescribing information. Grifols Biologicals Inc. June 2018
8. Rebinyn prescribing information. Novo Nordisk. June 2020.
9. Rixubis prescribing information. Baxalta. June 2020.
10. National Hemophilia Foundation. Bleeding Disorders A-Z/Types/Hemophilia B. Accessed at: <https://www.hemophilia.org/bleeding-disorders-a-z/types/hemophilia-b>.
11. Medical and Scientific Advisory Committee. MASAC recommendation regarding doses of clotting factor concentrate in the home. MASAC Document #242. June 2016.
12. Medical and Scientific Advisory Committee. MASAC recommendation concerning prophylaxis. MASAC Document #241. February 2016.
13. Medical and Scientific Advisory Council (MASAC) MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. Document #263. September 2020.
14. Srivastave A, Santagostino E, Dougall A, et al. World Federation of Hemophilia Guidelines for the Management of Hemophilia. 3rd edition. August 2020.
15. Medical and Scientific Advisory Committee. MASC Document 260 – Management of Chronic Pain in Persons with Bleeding Disorders: Guidance for Practical Application of The Centers for Disease Control’s Opioid Prescribing Guidelines. March 2020.
16. Fibryga Prescribing Information. Octapharma USA Inc. December 2020.
17. RiaSTAP Prescribing Information. CSL Behring LLC. June 2021.
18. National Hemophilia Foundation. Bleeding disorders, types of bleeding disorders, other factor deficiencies, Factor I. Accessed at <https://www.hemophilia.org/Bleeding-Disorders/Types-of-Bleeding-Disorders/Other-Factor-Deficiencies/Factor-I>. Accessed January 2019.
19. Medical and Scientific Advisory Council (MASAC). MASAC Document 263 Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders. September 2020.

20. Medical and Scientific Advisory Council (MASAC). MASAC Document 242 Recommendations Regarding Doses of Clotting Factor Concentrate in the Home. June 2016.
21. Medical and Scientific Advisory Committee. MASC Document 260 – Management of Chronic Pain in Persons with Bleeding Disorders: Guidance for Practical Application of The Centers for Disease Control’s Opioid Prescribing Guidelines. March 2020.
22. Advate prescribing information. Shire. December 2018.
23. Adynovate prescribing information. Shire. July 2021.
24. Afstyla prescribing information. CSL Behring. April 2021.
25. Alphanate Prescribing Information. Grifols Biologicals LLC. March 2021.
26. Eloctate prescribing information. Biogen. December 2020.
27. Esperoct prescribing information. Novo Nordisk. 2019.
28. Hemofil M prescribing information. Baxalta US Inc. June 2018.
29. Humate-P Prescribing Information. CSL Behring LLC. June 2020.
30. Jivi Prescribing Information. Bayer HealthCare LLC. August 2018.
31. Koāte-DVI prescribing information. Grifols Therapeutics Inc. June 2018.
32. Kogenate FS prescribing information. Bayer. December 2019.
33. Kovaltry prescribing information. Bayer. October 2021.
34. NovoEight prescribing information. Novo Nordisk. July 2020.
35. Nuwiq prescribing information. Octapharma. June 2021.
36. Recombinate prescribing information. Shire. February 2021.
37. Vonvendi Prescribing Information. Baxalta US Inc. February 2019.
38. Wilate Prescribing Information. Octapharma USA Inc. November 2019.
39. Xyntha prescribing information. Wyeth. August 2020.
40. National Hemophilia Foundation. Bleeding disorders A-Z/Types/Hemophilia A. Accessed at <https://www.hemophilia.org/bleeding-disorders-a-z/types/hemophilia-a>.
41. Medical and Scientific Advisory Committee. MASAC recommendation regarding doses of clotting factor concentrate in the home. MASAC Document #242. June 2016.
42. National Hemophilia Foundation. Steps for Living. The Basics of Bleeding Disorders/Treatment Basics. 2016.
43. Medical and Scientific Advisory Council (MASAC) MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. Document #263. September 2020.
44. Dimichele DM, Hoots WK, Pipe SW, et al. International workshop on immune tolerance induction: consensus recommendations. Haemophilia (2007), 13 (Suppl. 1), 1-22.

45. Medical and Scientific Advisory Committee (MASAC). MASAC Document 258 - Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra®) for Hemophilia A with and without Inhibitors. March 2020.
46. National Hemophilia Foundation. One Size Does Not Fit All: Individualized Therapy. Dr Steven Pipe. September 2016. Accessed at <https://www.hemophilia.org/educational-programs/education/online-education/one-size-does-not-fit-all-individualized-therapy>
47. Srivastava A, Santagostino E, Dougall A, et al. World Federation of Hemophilia Guidelines for the Management of Hemophilia. 3rd edition. August 2020.
48. CDC Centers for Disease Control and Prevention. Inhibitors and Hemophilia. Accessed at <https://www.cdc.gov/ncbddd/hemophilia/inhibitors.html>
49. National Hemophilia Foundation Bleeding Disorders A-Z Overview Inhibitors Treatment for Inhibitors. <https://www.hemophilia.org/bleeding-disorders-a-z/overview/inhibitors/treatment-for-inhibitors>
50. National Hemophilia Foundation. Bleeding Disorders A-Z/ Overview/ Inhibitors/ Immune Tolerance. Accessed at <https://www.hemophilia.org/bleeding-disorders-a-z/overview/inhibitors/immune-tolerance>
51. gov. NCT04023019. Treatment of Hemophilia A Individuals With FVIII Inhibitors (MOTIVATE). Accessed at: <https://clinicaltrials.gov/ct2/show/NCT04023019?term=NCT04023019&draw=2&rank=1>
52. Medical and Scientific Advisory Committee. MASAC Document 260 – Management of Chronic Pain in Persons with Bleeding Disorders: Guidance for Practical Application of The Centers for Disease Control’s Opioid Prescribing Guidelines. March 2020.
53. James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Advances 12 January 2021. Volume 5, Number 1. 280-300.
54. Medical and Scientific Advisory Committee. MASAC Document 266 – MASAC Recommendations Regarding the Treatment of von Willebrand Disease. March 2021.
55. NovoSeven RT Prescribing Information. Novo Nordisk Inc. July 2020.
56. Sevenfact Prescribing Information. HEMA Biologics, LLC. April 2020.
57. National Hemophilia Foundation. Bleeding disorders A-Z/Types/Hemophilia A. Accessed at <https://www.hemophilia.org/bleeding-disorders-a-z/types/hemophilia-a>.
58. National Hemophilia Foundation. Bleeding Disorders A-Z/Types/Hemophilia B. Accessed at: <https://www.hemophilia.org/bleeding-disorders-a-z/types/hemophilia-b>.

59. Medical and Scientific Advisory Council (MASAC) MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. Document #263. September 2020.
60. National Hemophilia Foundation Bleeding Disorders A-Z Overview Inhibitors Treatment for Inhibitors |National Hemophilia Foundation
61. Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia individuals with inhibitors. *J Thromb Haemost* 2007; 5: 1904-13.
62. National Organization for Rare Disorders (NORD). Rare Disease Database. Acquired Hemophilia. Accessed at: <https://rarediseases.org/rare-diseases/acquired-hemophilia/>.
63. National Hemophilia Foundation. Bleeding Disorders A-Z/Types/Other Factor Deficiencies/Factor VII. Accessed at: <https://www.hemophilia.org/bleeding-disorders-a-z/types/other-factor-deficiencies/factor-vii>.
64. Napolitano M, Glansly-Blalzot M, Dolce A, et al. Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). *Haematologica* 2013 Apr; 98(4):538-44.
65. National Hemophilia Foundation. Bleeding Disorders A-Z/Types/Inherited Platelet Disorders. Accessed at: <https://www.hemophilia.org/bleeding-disorders-a-z/types/inherited-platelet-disorders>.
66. Srivastava A, Santagostino E, Dougall A, et al. World Federation of Hemophilia Guidelines for the Management of Hemophilia. 3rd edition. August 2020.
67. Dimichele DM, Hoots WK, Pipe SW, et al. International workshop on immune tolerance induction: consensus recommendations. *Haemophilia* (2007), 13 (Suppl. 1), 1-22.
68. Ljung R, Auerswald G, Benson G, et al. Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat individuals. *Eur J Haematol*. 2019;102:111-122.
69. Medical and Scientific Advisory Committee. MASC Document 260 – Management of Chronic Pain in Persons with Bleeding Disorders: Guidance for Practical Application of The Centers for Disease Control’s Opioid Prescribing Guidelines. March 2020.
70. Coagadex Prescribing Information. Bio Products Laboratory USA. December 2020.
71. National Hemophilia Foundation. Bleeding Disorders, Types of Bleeding Disorders, Other Factor Deficiencies, Factor X. Accessed at <https://www.hemophilia.org/Bleeding-Disorders/Types-of-Bleeding-Disorders/Other-Factor-Deficiencies/Factor-X>.

72. Brown DL, Kouides PA. Diagnosis and treatment of inherited Factor X deficiency. *Haemophilia*. 2008;14, 1176-1182.
73. National Hemophilia Foundation MASAC Recommendations number 242. Recommendations Regarding Doses of Clotting Factor Concentrate in the Home. June 2016.
74. Medical and Scientific Advisory Committee. MASAC Document 260 – Management of Chronic Pain in Persons with Bleeding Disorders: Guidance for Practical Application of The Centers for Disease Control’s Opioid Prescribing Guidelines. March 2020.